Skip to main content

Table 3 Distribution of the different mutations

From: EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer

Patient

KRAS mutations

BRAF mutations

PIK3CA mutations

1

12ALA

wt

Wt

2

12ALA

wt

Wt

3

12ALA

wt

Wt

4

12ALA

wt

Wt

5

12ARG

wt

Wt

6

12ARG

wt

Wt

7

12ARG

wt

Wt

8

12ASP

wt

E542K

9

12ASP

wt

E542K

10

12ASP

wt

E545K/D**

11

12ASP

wt

E545K/D

12

12ASP

wt

E545K/D

13

12ASP

wt

Wt

14

12ASP

wt

Wt

15

12ASP

wt

Wt

16

12ASP

wt

Wt

17

12ASP

wt

Wt

18

12ASP

wt

Wt

19

12ASP

wt

Wt

20

12ASP

wt

Wt

21

12ASP

wt

Wt

22

12ASP

wt

Wt

23

Mut*

NA

NA

24

12CYS

wt

E542K

25

12CYS

wt

Wt

26

12CYS

wt

Wt

27

12SER

wt

Wt

28

12SER

wt

Wt

29

12VAL

wt

E542K

30

12VAL

wt

H1047R

31

12VAL

wt

Wt

32

12VAL

wt

Wt

33

12VAL

wt

Wt

34

12VAL

wt

Wt

35

12VAL

wt

Wt

36

13ASP

wt

Wt

37

13ASP

wt

Wt

38

13ASP

wt

Wt

39

13ASP

wt

Wt

40

13ASP

wt

Wt

41

13CYS

wt

Wt

42

wt

E600

Wt

43

wt

E600

Wt

44

wt

E600

Wt

45

wt

wt

E542K

46

wt

wt

E542K

47

wt

wt

E542K

48

wt

wt

E545K/D

49

wt

wt

E545K/D

  1. *KRAS mutational status assessed in external institution, but not specified.
  2. **The DxS assay does not discriminate between the E545K and E545D mutation.